MedTrace Logo

Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users

NCT02070692 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2017-07-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to study whether a drug called tamoxifen can reduce vaginal bleeding in women who are using the Etonogestrel contraceptive implant.

Conditions

  • Menstruation Disturbances

Interventions

DRUG

Tamoxifen

7 day course of tamoxifen during an episode of irregular vaginal bleeding

DRUG

Placebo

7 day course of placebo during an episode of irregular vaginal bleeding

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02070692 on ClinicalTrials.gov